04.11.2018 | Investors

Allergan to Review Presentation at EASL in Paris of Year 2 Analysis of the Phase 2b CENTAUR Study Cenicriviroc (CVC) Treatment for Adults with Non-Alcoholic Steatohepatitis

Allergan plc will host a conference call and webcast on Thursday, April 12, 2018 at 12:00p.m. EST to review the year 2 analysis of the Phase 2b CENTAUR Study of Cenicriviroc (CVC) for adults with Non-Alcoholic Steatohepatitis.

This data will be presented at the European Association for the Study of the Liver (EASL) Meeting earlier on Thursday, April 12, 2018 in Paris, France. Top-line data from the study was also presented in September 2017.

Dial-in Information

U.S./Canada: (877) 251-7980
International: (706) 643-1573
Conference ID: 2689057

Replay Information

A replay of the conference call will be available approximately two hours after it ends and will remain available through 11:30p.m. ET on May 12, 2018. The replay may be accessed by dialing (855) 859-2056 or (404) 537-3406, and entering the Conference ID 2689057.

To access the webcast, please visit Allergan's Investor Relations website at www.allergan.com/investors/events-presentations

Media Contacts
Amy Rose
Global Corporate Media Relations
+1 (862) 289 3072
Lisa Brown
Global Corporate Media Relations
+1 (862) 261 7320
Fran DeSena
U.S. Product Media Relations
+1 (862) 261 8820
Mark Marmur
International Communications & Public Relations
+44 7725 758677

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Karina Calzadilla
Investor Relations
+1 (862) 261 7488